We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Map Pharmaceuticals, Inc. (MM) | NASDAQ:MAPP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.98 | 0 | 01:00:00 |
From May 2019 to May 2024
Allergan Inc. (AGN) has agreed to pay Map Pharmaceuticals Inc. (MAPP) $60 million under a collaboration deal involving the latter's Levadex migraine drug.
Map plans to file for approval of the treatment in the first half of this year. Levadex is an inhaled version of a drug administered for decades in emergency rooms and doctors' offices through an intravenous line.
The pair plan to take advantage of Allergan's existing sales force dedicated to headache specialists. Last year, Allergan's Botox--used for medical purposes as well as for fighting wrinkles--was approved for marketing in the U.S. to treat migraines.
Allergan agreed to pay Map up to an additional $97 million for reaching regulatory milestones associated with the initial indication. The companies will jointly develop Levadex for additional indications.
Allergan closed Friday at $69.08 while Map finished at $15.50. Neither was active premarket.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com
1 Year Map Pharmaceuticals, Inc. (MM) Chart |
1 Month Map Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
